secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2025-11-20T23:59:59+00:00
Accession:  0001437749-25-035860
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum's PIPE-307 Phase 2 RRMS trial misses primary endpoint
---------------------------------------------------------------

- Phase 2 VISTA trial of M1 receptor antagonist PIPE-307 did not meet primary or secondary efficacy endpoints.
- No significant change in binocular 2.5% low contrast letter acuity (LCLA) across treatment arms.
- PIPE-307 demonstrated acceptable safety and tolerability at both doses.
- Company will continue to analyze exploratory endpoints and plans future medical meeting presentation.
- CEO and CMO express disappointment; focus remains on inflammatory and fibrotic disease pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925035860/0001437749-25-035860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925035860/ctnm20251117_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-035860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer